For most people struggling with weight, the problem is not motivation. It is biology.
The hormones that regulate hunger, blood sugar, and fat storage are working against the effort. The body defends its fat mass through appetite signals that become louder the more weight is lost. The harder you try, the harder the system pushes back. That is not a character flaw. That is physiology.
Semaglutide changes the conversation your body is having with itself.
At South Beach Wellness Center, Maribel Dixon, MSN, APRN FNP-C offers medically supervised semaglutide therapy for adults in Wesley Chapel, Land O’ Lakes, Lutz, and New Tampa. Every protocol starts with comprehensive lab work, includes ongoing monitoring, and is adjusted based on your results, not on a fixed schedule applied to every patient regardless of how they are responding.
Maribel Dixon, MSN, APRN FNP-C
Semaglutide is a GLP-1 receptor agonist, a class of medication that mimics glucagon-like peptide-1, a hormone your body naturally produces in response to food. GLP-1 plays a central role in regulating appetite, blood sugar, and digestion. Semaglutide activates GLP-1 receptors throughout the body at levels significantly higher than your body produces naturally, producing a sustained and clinically meaningful effect on all three systems.
It is administered as a once-weekly subcutaneous injection and is available in both brand-name and compounded formulations.
Semaglutide was originally developed for Type 2 diabetes management under the brand name Ozempic. Its weight loss application was later studied and approved under the brand name Wegovy at a higher dose. The mechanism is the same. The clinical data on both is extensive.
Semaglutide produces weight loss through three distinct biological pathways working simultaneously.
In the brain, semaglutide acts on the hypothalamus, the region that controls hunger, satiety, and food reward signaling. It reduces the drive to eat by decreasing appetite and significantly quieting what patients describe as food noise, the constant background pull toward food that makes sustained caloric reduction feel like a battle of willpower.
Patients on semaglutide consistently describe this as one of the most significant changes they experience. Food stops being a preoccupation. Eating becomes a response to genuine hunger rather than a constant negotiation.
In the digestive system, semaglutide slows the rate at which food leaves the stomach. Food stays in the stomach longer after eating, extending the feeling of fullness between meals and reducing the urge to snack or eat larger portions. You feel satisfied sooner and stay satisfied longer.
In the pancreas, semaglutide stimulates insulin release in response to meals while suppressing excess glucagon. The result is more stable blood sugar levels, reduced insulin spikes after eating, and an improved hormonal environment for fat metabolism. For patients with insulin resistance or pre-diabetes, this metabolic correction has benefits that extend well beyond weight loss.
Semaglutide has one of the most thoroughly studied clinical profiles of any weight loss medication currently available.
The STEP clinical trial program evaluated semaglutide at the Wegovy dose across thousands of patients. Average weight loss in the STEP 1 trial was 14.9 percent of body weight over 68 weeks in patients without diabetes. For a patient starting at 220 pounds, that is approximately 33 pounds of sustained fat loss.
Patients who remained on semaglutide maintained their weight loss. Patients who discontinued it regained a significant portion of the weight, which is consistent with the understanding that obesity is a chronic condition requiring ongoing management rather than a short-term problem with a finite treatment window.
Beyond weight loss, semaglutide has demonstrated cardiovascular benefits in the SELECT trial, showing a 20 percent reduction in major cardiovascular events in overweight and obese patients with established cardiovascular disease. The clinical case for semaglutide extends well beyond aesthetics.
Wegovy is the FDA-approved semaglutide formulation indicated specifically for chronic weight management. It follows a standardized dose titration schedule starting at 0.25 mg weekly and increasing over 16 to 20 weeks to the 2.4 mg maintenance dose. Availability has improved significantly since the initial post-approval shortage period.
Compounded semaglutide allows for individualized dosing that is not available with the standardized brand formulation. This is particularly valuable for patients who need a slower titration schedule due to side effects, patients who require a dose between the available brand increments, or patients for whom the standard titration pace produces intolerable gastrointestinal symptoms.
Compounded semaglutide is sourced from licensed compounding pharmacies. Maribel discusses the current availability and clinical appropriateness of both options at your consultation.
Semaglutide is clinically indicated for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as Type 2 diabetes, hypertension, high cholesterol, or cardiovascular disease.
Beyond the clinical criteria, semaglutide tends to be the strongest fit for patients who have struggled with persistent hunger and food cravings as the primary driver of their weight challenges, patients with insulin resistance or blood sugar dysregulation, and patients looking for a once-weekly protocol that does not require daily medication management.
It is not appropriate for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, or for patients with a history of pancreatitis. Maribel reviews your full health history and current medications at your consultation before making any recommendation.
Your first visit is a comprehensive consultation that includes a full health history review, physical exam, and lab work. Labs include fasting glucose, HbA1c, thyroid function, lipid panel, metabolic panel, and a complete blood count. Maribel uses this baseline to confirm candidacy, identify any metabolic factors that affect protocol design, and establish the benchmarks against which your progress will be measured. Body composition is assessed using our seca mBCA Alpha medical-grade analyzer. Your baseline visceral fat, skeletal muscle mass, body fat percentage, and phase angle are recorded so every subsequent scan shows exactly what is changing and what is not.
Maribel starts every patient at a conservative dose and titrates upward based on tolerance and response. The goal is the lowest effective dose that produces meaningful weight loss with manageable side effects. Not every patient needs the maximum dose to achieve their goals, and pushing dose escalation faster than the patient's tolerance warrants produces unnecessary side effects and dropout.
Follow-up labs are drawn at regular intervals throughout your program. Body composition scans are repeated to confirm that weight loss is coming from fat rather than lean tissue. Protocol adjustments are made based on what the data shows, not on a fixed schedule. This is the piece that most weight loss programs skip. Without ongoing monitoring, you are guessing. With it, every decision Maribel makes about your protocol is grounded in what your body is actually doing.
The most common side effects of semaglutide are gastrointestinal: nausea, mild constipation, and reduced appetite. These are most pronounced during dose escalation and typically improve as the body adjusts to each new dose level.
Strategies that consistently reduce side effect burden include starting at the lowest possible dose, increasing very gradually, eating smaller meals, staying well hydrated, avoiding high-fat meals particularly during early titration, and taking the injection at a consistent time each week.
Patients who find the standard titration pace produces intolerable nausea are strong candidates for compounded semaglutide, which allows slower, more granular dose increases that give the body more time to adapt at each level.
Maribel monitors side effects throughout your program and adjusts your protocol if they are affecting your quality of life or your ability to maintain the program.
One of the most important clinical considerations in GLP-1 therapy is the risk of muscle mass loss alongside fat loss. Semaglutide reduces overall caloric intake, and without adequate protein and resistance activity, a portion of the weight lost can come from lean tissue rather than fat.
This is not inevitable. It is manageable with the right protocol design.
Maribel monitors skeletal muscle mass at every body composition scan. If lean mass is declining at a rate that warrants concern, she adjusts protein targets, discusses resistance training, and considers whether additional supportive therapies are appropriate. Some patients add Lipo-B MICC injections or vitamin therapy to support their protocol during active weight loss.
The seca mBCA data makes this visible in a way that a standard scale never could. Catching muscle loss early and correcting course is one of the most important things a medically supervised program offers that self-directed GLP-1 use cannot.
How is semaglutide different from other weight loss medications?
Semaglutide works on the hormonal and neurological systems that regulate hunger and blood sugar rather than stimulating the central nervous system the way older appetite suppressants like phentermine do. The effect is more comprehensive, more sustained, and supported by a larger body of clinical evidence than any previous weight loss medication class.
How long does it take to see results?
Most patients notice reduced appetite within the first one to two weeks. Measurable weight loss typically begins in weeks two through four and accelerates as the dose increases over the titration period. Significant results are generally visible at the three-month mark with continued progress through six to twelve months of treatment.
Do I have to stay on semaglutide forever?
Not necessarily, but the data is clear that weight regain is common after discontinuation. Maribel discusses long-term strategy at your consultation and throughout your program. Some patients transition to a lower maintenance dose after reaching their goal. Others incorporate lifestyle changes substantial enough to maintain results without medication. This is an individual decision made with full information.
What is the difference between Wegovy and Ozempic?
Both contain semaglutide. Ozempic is approved for Type 2 diabetes management at doses up to 2 mg. Wegovy is approved specifically for chronic weight management at a 2.4 mg maintenance dose. The mechanism is identical. The approved indication and maximum dose differ.
Can I use semaglutide if I have Type 2 diabetes?
Yes. Semaglutide was originally developed for Type 2 diabetes and has an extensive safety and efficacy record in diabetic patients. If you have diabetes, your protocol will be coordinated with your existing diabetes management and monitored closely for changes in blood sugar that may require medication adjustments.
How does compounded semaglutide differ from brand-name Wegovy?
The active ingredient is the same. Compounded semaglutide is prepared by a licensed compounding pharmacy and allows for dose flexibility not available with the standardized brand formulation. It is particularly useful for patients who need a slower titration pace. Maribel discusses both options and their current availability at your consultation.
What happens if I stop taking semaglutide?
Most patients experience gradual weight regain after stopping, particularly if lifestyle modifications have not been implemented alongside the medication. This is consistent with the clinical understanding of obesity as a chronic condition. Stopping semaglutide should be a planned decision made in partnership with Maribel rather than an abrupt discontinuation.
Schedule your medical weight loss consultation with Maribel Dixon, MSN, APRN FNP-C at South Beach Wellness Center. Your consultation includes comprehensive lab work, a seca mBCA body composition scan, and a full protocol recommendation before you commit to anything.
